RadarScope: GH — Analiza Fundamentala

Market Cap

$20.9B

P/E Ratio

-46.5

Profit Margin

-40.1%

ROE

184.3%

📈 Earnings Report — 2026-05

Ultimul trimestru raportat

EPS Actual

$-0.85

▲ 5.6% QoQ▼ 73.5% YoY

EPS Estimat

$-0.806

Miss by 5.5%

Revenue Actual

$302M

▲ 7.3% QoQ▲ 48.3% YoY

Revenue Estimat

$279M

Beat by 8.1%

Istoric Ultimele 4 Trimestre

2026-05

EPS Actual

$-0.85

EPS Est.

$-0.806

Revenue

$302M

Beat/Miss

Miss by 5.5%

2026-02

EPS Actual

$-0.9

EPS Est.

$-0.76677

Revenue

$281M

Beat/Miss

Miss by 17.4%

2025-10

EPS Actual

$-0.39

EPS Est.

$-0.48

Revenue

$265M

Beat/Miss

Beat by 18.7%

2025-07

EPS Actual

$-0.44

EPS Est.

$-0.52

Revenue

$232M

Beat/Miss

Beat by 15.4%

Urmatorul Raport

Data

2026-07-29

EPS Estimat

$-0.42

Revenue Estimat

$314M

📊 Scoruri Companie

Crestere 8/10

Revenue & Profit Growth

Evaluare 4/10

P/E · P/B · P/S

Calitate 6/10

Marje · ROE · Datorii

Risc 7/10

Beta · Market Cap

📈 Date Financiare Istorice in miliarde USD

💰 Revenue

📊 Net Profit

💵 Cash Flow

Operating (albastru) · Free (violet)

🏦 Cash & Datorii

Cash (verde) · Long-term Debt (rosu)

💸 Operating Expenses

🤖 Analiza RadarScope AI

Analiza indisponibila temporar.

💡 Vezi datele de mai jos

🐂 BULL CASE

Date financiare solide

Pozitie competitiva puternica

🐻 BEAR CASE

Evaluare ridicata

Incertitudine macro

TINE Analiza manuala recomandata

📊 Metrici Fundamentale

P/E TTM-46.5

P/B TTM-114.36

P/S TTM19.36

EV/EBITDA—

Gross Margin64.9%

Operating Margin-41.4%

Net Margin-40.1%

ROE184.3%

ROA-22.6%

Debt/Equity—

Current Ratio4.68

FCF Yield-1.1%

Dividend Yield—

Beta1.62

💰 Venituri & Profit (ultimele trimestre)

Trimestru	Revenue	Gross Profit	Net Income	EPS
2025-12	$982.0M	$633.0M	$-416.3M	$-3.32
2024-12	$739.0M	$449.2M	$-436.4M	$-3.56
2023-12	$563.9M	$336.9M	$-479.4M	$-4.28
2022-12	$449.5M	$293.2M	$-654.6M	$-6.41

🏢 Profil Companie

CEOHelmy Eltoukhy

Angajati1999

IPO2018-10-04

Websitehttps://guardanthealth.com...

52W High$161.47

52W Low$40.35

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Hea...

🎯 Score Breakdown

Calitate Companie (Q) 6/10

Risc Speculativ (R) 7/10

Scor AI RadarScope 50/100

VERDICT FINAL

TINE

Analiza manuala recomandata

🔒 Analiza completa disponibila cu cont SignalRadar